Monoclonal antibodies to CD44 epitopes on mouse endothelium

Hybridoma and Hybridomics

Volumn 21, Issue 5, 2002, Pages 339-349

  Davern, S M ^a   Lankford, P K ^a   Foote, L J ^a   Kennel, S J ^a  

^a OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HERMES ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 133 13A; MONOCLONAL ANTIBODY 531 22A; MONOCLONAL ANTIBODY 531 2A; MONOCLONAL ANTIBODY 531 30A; MONOCLONAL ANTIBODY 531 32A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; BINDING COMPETITION; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNIZATION; IMMUNOPRECIPITATION; LUNG ENDOTHELIUM; MASS SPECTROMETRY; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RAT; TUMOR CELL; WESTERN BLOTTING;

ANIMALIA; MURINAE;

EID: 0036936756     PISSN: 15368599     EISSN: None     Source Type: Journal    
DOI: 10.1089/153685902761022689     Document Type: Article

References (49)

1. Haegel H, Tolg C, Hofmann M, and Ceredig R: Activated mouse astrocytes and T cells express similar CD44 variants. Role of CD44 in astrocyte/T cell binding. J Cell Biol 1993;122:1067-1077.
2. Bajorath J, Greenfield B, Munro SB, Day AJ, and Aruffo A: Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem 1998;273:338-343.
3. Knudson W, Chow G, and Knudson CB: CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 2002;21:15-23.
4. Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR, and McCarthy JB: A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol 1992;116:521-531.
5. Knutson JR, Iida J, Fields GB, and McCarthy JB: CD44/chondroitin sulfate proteoglycan and alpha 2 beta 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell 1996;7:383-396.
6. Toyama-Sorimachi N, Sorimachi H, Tobita Y, Kitamura F. Yagita H, Suzuki K, and Miyasaka M: A novel ligand for CD44 is serglycin, a hematopoietic cell lineage-specific proteoglycan. Possible involvement in lymphoid cell adherence and activation. J Biol Chem 1995;270:7437-7444.
7. Kulseth MA, Kolset SO, and Ranheim T: Stimulation of serglycin and CD44 mRNA expression in endothelial cells exposed to TNF-alpha and IL-1alpha. Biochim Biophys Acta 1999;1428:225-232.
8. Weber GF, Ashkar S, Glimcher M J, and Cantor H: Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996;271:509-512.
9. Romaris M, Bassols A, and David G: Effect of transforming growth factor-beta 1 and basic fibroblast growth factor on the expression of cell surface proteoglycans in human lung fibroblasts. Enhanced glycanation and fibronectin-binding of CD44 proteoglycan, and down-regulation of glypican. Biochem J 1995;310:73-81.
10. Johnson P, Maiti A, Brown KL, and Li R: A role for the cell adhesion molecule CD44 and sulfation in leukocyte-endothelial cell adhesion during an inflammatory response. Biochem Pharmacol 2000;59:455-465.
11. Bajorath J: Molecular organization, structural features, and ligand binding characteristics of CD44, a highly variable cell surface glycoprotein with multiple functions. PROTEINS: Structure, Function and Genetics 2000;39:103-111.
12. Yamashita Y, Hirano H, and Hodes RJ: Tissue-specific and growth-regulated expression of CD44 variable exon determinants in the mouse. Cell Immunol 1997;176:22-33.
13. Naot D, Sionov RV, and Ish-Shalom D: CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319.
14. Hofmann M, Rudy W, Gunthert U, Zimmer SG, Zawadzki V, Zoller M, Lichtner RB, Herrlich P, and Ponta H: A link between ras and metastatic behavior of tumor cells: Ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells. Cancer Res 1993;53:1516-1521.
15. Asosingh K, Gunthert U, De Rave H, Van Riet I, Van Camp B, and Vanderkerken K: A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 2001;61:2862-2865.
16. Stauder R, Eisterer W, Thaler J, and Gunthert U: CD44 variant isoforms in non-Hodgkin's lymphoma: A new independent prognostic factor. Blood 1995;85:2885-2899.
17. Hughes EN, Mengod G, and August JT: Murine cell surface glycoproteins. Characterization of a major component of 80, 000 daltons as a polymorphic differentiation antigen of mesenchymal cells. J Biol Chem 1981;256:7023-7027.
18. Hughes EN, Colombatti A, and Auguat JT: Murine cell surface glycoproteins. Purification of the polymorphic Pgp-1 antigen and analysis of its expression on macrophages and other myeloid cells. J Biol Chem 1983;258:1014-1021.
19. Wolffe EJ, Gause WC, Pelfrey CM, Holland SM, Steinberg AD, and August JT: The cDNA sequence of mouse Pgp-1 and homology to human CD44 cell surface antigen and proteoglycan core/link proteins. J Biol Chem 1990;265:341-347.
20. Rosel M, Seiter S, and Zoller M: CD44v10 expression in the mouse and functional activity in delayed type hypersensitivity. J Cell Physiol 1997;171:305-317.
21. Trowbridge IS, Lesley J, Schulte R, Hyman R, and Trotter J: Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissue. Immunogenetics 1982;15:299-312.
22. Lesley J, Kincade PW, and Hyman R: Antibody-induced activation of the hyaluronan receptor function of CD44 requires multivalent binding by antibody. Eur J Immunol. 1993;23:902-909.
23. Ohizumi I, Taniguchi K, Saito H, Kawata H, Tsunoda S-I, makimoto H, Wakai Y, Tsutsumi Y, Nakagawa S, Utoguchi N, Kaiho S-I, Ohsugi Y, and Mayumi T: Suppression of solid tumor growth by a monoclonal antibody against tumor vasculature in rats: Involvement of intravascular thrombosis and fibrinogenesis. Int J Cancer 1999;82:853-859.
24. Kennel S J, Lankford T, Galloway P, and Witschi HP: A new monoclonal antibody to study mouse macrophage antigen during BHT-induced lung injury and repair. Toxicology 1989;55:103-116.
25. Lokeshwar VB, Iida N, and Bourguignon YW: The cell adhesion molecule, GP116, is a new CD44 variant (exl4/vl0) involved in hyaluronic acid binding and endothelial cell proliferation. J Biol Chem 1996;271:23853-23864.
26. Ohizumi I, Taniguchi K, Saito H, Kawate H, Tsunoda S, Makimoto H, Wakai Y, Tsutsumi Y, Nakagawa S, Utoguchi N, Kaiho S, Ohsugi Y, and Mayumi T: Suppression of solid tumor growth by a monoclonal antibody against tumor vasculature in rats: Involvement of intravascular thrombosis and fibrinogenesis. Int J Cancer 1999;82:853-859.
27. Terzaghi-Howe M: Inhibition of carcinogen-altered rat tracheal epithelial cell proliferation of normal epithelial cells in vivo. Carcinogenesis 1987;8:145-150.
28. Yuhas JM, Pazmino NH, Proctor JO, and Toya RE: A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor. Cancer Res 1974;34:722-728.
29. Schulman M, Wilke CD, and Kohler G: A better cell line for making hybridomas secreting specific specific antibodies. Nature 1978;276:269-270.
30. De St Groth FS, and Scheidegger D: Production of monoclonal antibodies: Strategy and tactics. J Immunol Methods 1980;35:1-21.
31. Kennel SJ, Lankford T, and Flynn KM: Therapy of a murine sarcoma using synergic monoclonal antibodies. Cancer Res 1983;2843-2848.
32. Friesel R, and Maciag T: Internalization and degradation of heparin binding growth factor-I by endothelial cells. Biochem Biophys Res Commun 1988;151:957-964.
33. Kennel SJ, Foote LJ, and Flynn KM: Tumor antigen on benign adenomas on murine lung carcinomas quantitated by a two-site monoclonal antibody assay. Cancer Res 1986;46:707-712.
34. Kennel SJ, Foote LJ, Falcioni R, Sonnenberg A, Stringer CD, Crouse C, and Hemler ME: Analysis of the tumor-associated antigen TSP-180. J Biol Chem 1989;264:15515-15521.
35. Kennel S J, Lankford TK, Foote LJ, Shinpock SG, and Stringer C: CD44 expression on murine tissues. J Cell Sci 1993;104:373-382.
36. McConahey PJ, and Dixon FJ: A method of trace iodination of proteins for immunologic studies. Int Arch Allergy 1966;29:185-189.
37. Garg PK, Alston KL, Welsh PS, and Zalutsky MR: Enhanced binding and inertness to dehalogenation of melantropic peptides labeled using N-succinimidyl 3-iodobenzoate. Bioconjugate Chem 1996;7:233-239.
38. Vaidyanathan G, Affleck DJ, and Zalutsky MR: Method for radioiodination of proteins using N-succinimidyl 3-hydyoxy-4-iodobenzoate. Bioconjugate Chem 1997;8:724-729.
39. Kennel S J, Lankford T, Hughes B, and Hotchkiss JA: Quantitation of a murine lung endothelial cell protein, P112, with a double monoclonal antibody assay. Lab Invest 1988;59:692-701.
40. Kennel S J, Foote LJ, and Lankford PK: Analysis of surface proteins of mouse lung carcinomas using monoclonal antibodies. Cancer Res 1981;41:3465-3470.
41. Teder P, Vandivier RW, Jiand D, Liang J, Cohn L, Pure E, Henson PM, and Noble PW: Resolution of lung inflammation by CD44. Science 2002;296:155-158.
42. Cabrera PV, Blanco G, Gravisaco MJ, Alvarez E, and Hajos S: Zymosan modulates CD44 isoform expression in a murine model of inflammation resembling rheumatoid arthritis synovitis. J Rheumatol 2001;28:943-949.
43. Takagi T, Okamoto R, Suzuki K, Hayashi T, Sato M, Sato M, Kurosaka N, and Koshino T: Up-regulation of CD44 in rheumatoid chondrocytes. Scand J Rheumatol 2001;30:110-113.
44. Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P, and Zoller M: Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 1992;257:682-685.
45. Welsh CF, Zhu D, and Bourguignon LY: Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol 1995;164:605-612.
46. Iida N, and Bourguignon LY: New CD44 splice variants associated with human breast cancers. J Cell Physiol 1995;162:127-133.
47. Van der Voort R, Manten-Horst E, Smit L, Ostermann E, van den Berg F, and Pals ST: Binding of cell-surface expressed CD44 to hyaluronate is dependent on splicing and cell type. Biochem Biophys Res Commun 1995;214:137-144.
48. Yu Q, and Toole BP: A new alternatively spliced exon between v9 and vl0 provides a molecular basis for synthesis of soluble CD44. J Biol Chem 1996;271:20603-20607.
49. Lokeshwar VB, and Bourguignon LY: Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. J Biol Chem 1991;266:17983-17989.